Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AN2 Therapeutics Q3 EPS $(0.65) Beats $(0.70) Estimate

Author: Benzinga Newsdesk | November 09, 2023 06:32pm
AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.70) by 7.14 percent. This is a 10.17 percent decrease over losses of $(0.59) per share from the same period last year.

Posted In: ANTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist